Clinical Trials
15 trialsNCT06284122 2026-06-05
MorningLyte
The Lymphoma Academic Research Organisation
Phase 3 Recruiting
NCT05139017 2026-06-04
waveLINE-003
Merck Sharp & Dohme LLC
Phase 2/3 Recruiting
NCT06084936 2026-06-03
GLOBRYTE
Hoffmann-La Roche
Phase 3 Recruiting
NCT07139873 2026-06-03
A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6)
Dizal Pharmaceuticals
Phase 3 Recruiting
NCT06191744 2026-06-02
EPCOREâ„¢FL-2
Genmab
Phase 3 Recruiting
NCT06846671 2026-05-29
CaDAnCe-302
BeOne Medicines
Phase 3 Recruiting
NCT06911502 2026-05-20
A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)
Celgene
Phase 3 Recruiting
NCT06091254 2026-05-19
OLYMPIA-1
Regeneron Pharmaceuticals
Phase 3 Recruiting
NCT06970743 2026-05-11
CaDAnCe-303
BeOne Medicines
Phase 3 Recruiting
NCT07225985 2026-05-11
Pralatrexate With Bendamustine and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma
Fred Hutchinson Cancer Center
Phase 1/2 Recruiting
NCT05848765 2026-05-05
REFRACT
University of Birmingham
Phase 2 Recruiting
NCT04844866 2026-04-29
DALY 2-EU
Miltenyi Biomedicine GmbH
Phase 2 Recruiting
NCT06522737 2026-04-06
TERZO
SecuraBio
Phase 3 Recruiting
NCT06561347 2026-03-31
ZEBRA
Massachusetts General Hospital
Phase 2 Recruiting
NCT06483048 2026-03-16
MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer
Mayo Clinic
Phase 1 Recruiting